Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

HemoShear, LLC, is pleased to announce that it was awarded a Phase 1 Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

7 Apr 2011

ALR announces medical research grant awards to cure lupus

The Alliance for Lupus Research – the world's largest private funder of lupus research – today announced its most recent medical research grant awards, totaling $3.6 million, which support the ALR mission of finding better treatments and ultimately preventing and curing systemic lupus erythematosus, a debilitating autoimmune disease.

7 Apr 2011

AMPK suppression and SREBP activation are root cause of fatty liver and hyperlipidemia in type 2 diabetes

Researchers from Boston University School of Medicine, including Yu Li, PhD, and other colleagues, have demonstrated that a nutrient sensing pathway is involved in the disruption of cellular lipid homeostasis in obese and insulin resistant mice fed a diet high in fat and sucrose.

6 Apr 2011

LDL particles may be a more accurate measure of subclinical atherosclerosis than LDL cholesterol

LipoScience, Inc., a highly innovative diagnostic company that is advancing patient care by developing high value proprietary blood tests using nuclear magnetic resonance (NMR) technology, today announced presentations of two clinical studies "from the podium" at the 60th Annual Scientific Session of the American College of Cardiology.

6 Apr 2011

FDA approves NeuroVasx cPAX Aneurysm Treatment System

NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.

6 Apr 2011

Antidepressants may increase heart attack or stroke risk in men: Study

...

3 Apr 2011

CardioNexus to launch Panasonic CardioHealth Station at American College of Cardiology 2011 Annual Scientific Sessions

CardioNexus Corporation an affiliated company of Panasonic Healthcare Co. Ltd., will introduce Panasonic CardioHealth® Station at the 2011 Annual Scientific Sessions of the American College of Cardiology.

From PHC Europe B.V. 31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Prostatic artery embolization comparable to transurethral resection

A new interventional radiology treatment that blocks blood supply to men's enlarged prostate glands shows comparable clinical results to transurethral resection of the prostate (or TURP), considered the gold standard (or most common) treatment. However, this minimally invasive treatment-prostatic artery embolization-has none of the risks associated with TURP, such as sexual dysfunction, urinary incontinence, blood loss and retrograde ejaculation, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago.

30 Mar 2011

Study links specific cardiovascular risk factors to AF episodes

Reducing cardiovascular risk factors like high blood pressure, smoking, diabetes and being overweight could potentially reduce more than half of all cases of atrial fibrillation, according to research reported in Circulation: Journal of the American Heart Association.

29 Mar 2011

New pill may protect DNA from radiation damage

The Japanese nuclear crisis has caused a surge in the demand of potassium iodide, causing shortages not only in Japan, but as far away as California, western Canada, and even southeastern Russia. Although potassium iodide does not provide generalized radiation protection because it only shields the thyroid, manufacturers and pharmacies are being bombarded with orders as the radiation hysteria mounts.

28 Mar 2011

Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.

28 Mar 2011

New study: Coronary calcium scan can help reduce risk of heart disease

A new study of coronary artery calcium scanning - a simple, noninvasive test that gives patients baseline information about plaque in their coronary arteries—has shown that the scan helps them make heart-healthy lifestyle changes and lower their heart disease risk factors.

24 Mar 2011

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

NasVax announces the success of a Phase 2a clinical trial of a new oral immunotherapy for non-alcoholic steatohepatitis (NASH), an inflammatory disease associated with fatty liver disease and the metabolic syndrome.

21 Mar 2011

Journal of Clinical Lipidology publishes LipoScience LDL particle study results against CVD

LipoScience, Inc., a highly innovative diagnostic company that is advancing patient care by developing high value proprietary blood tests using nuclear magnetic resonance technology, today announced publication of a clinical study in the Journal of Clinical Lipidology demonstrating that in many people, low density lipoprotein cholesterol is a less accurate predictor of cardiovascular disease events than LDL particle number.

19 Mar 2011

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

The Montreal Heart Institute today announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis REgression?) study of CER-001 in patients with acute coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases.

16 Mar 2011

Human growth, height, size: Reasons to be small

Almost everybody these days thinks that it is best to be tall, meaning much taller than the average traditional height of Asian populations, and even taller than the current average height of populations in high-income countries. It is also often believed – though people might be shy to admit this – that tall people are intrinsically superior to short people. The expressions 'look up to' and 'look down on' are significant.

15 Mar 2011

Specific inflammatory factor may be responsible for aortic stenosis development

Research from Karolinska Institutet in Sweden shows that a specific inflammatory factor may be important in the development of the heart valve disease aortic stenosis. The results suggest that anti-inflammatory medication could be a possible new treatment.

15 Mar 2011

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein therapies to treat cardiovascular and metabolic diseases, today announced the start of the Phase 2 CHI-SQUARE study of CER-001 in patients with acute coronary syndrome.

15 Mar 2011

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

BioInvent International AB announces today the dosing of the first patient in the phase II study of the Company's antibody, BI-204. The product candidate is being developed for secondary prevention of cardiovascular events in patients with acute coronary syndrome.

14 Mar 2011

Atherosclerosis News and Research

Further Reading

NIH awards HemoShear with Phase I SBIR grant to develop rodent liver system

ALR announces medical research grant awards to cure lupus

AMPK suppression and SREBP activation are root cause of fatty liver and hyperlipidemia in type 2 diabetes

LDL particles may be a more accurate measure of subclinical atherosclerosis than LDL cholesterol

FDA approves NeuroVasx cPAX Aneurysm Treatment System

Antidepressants may increase heart attack or stroke risk in men: Study

CardioNexus to launch Panasonic CardioHealth Station at American College of Cardiology 2011 Annual Scientific Sessions

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Prostatic artery embolization comparable to transurethral resection

Study links specific cardiovascular risk factors to AF episodes

New pill may protect DNA from radiation damage

Pathway Medical initiates enrollment in JETSTREAM G3 Calcium Study in peripheral artery disease

New study: Coronary calcium scan can help reduce risk of heart disease

NasVax reports positive results from Phase 2a trial of oral immunotherapy for non-alcoholic steatohepatitis

Journal of Clinical Lipidology publishes LipoScience LDL particle study results against CVD

Montreal Heart Institute and Cerenis commence CER-001 Phase 2 study in acute coronary syndrome

Human growth, height, size: Reasons to be small

Specific inflammatory factor may be responsible for aortic stenosis development

Cerenis commences CER-001 Phase 2 CHI-SQUARE study in patients with ACS

BioInvent commences BI-204 phase II study in patients with acute coronary syndrome

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News